Business-overview
The UK pharmaceutical industry has grown significantly in recent years, particularly in the generic medicines segment. The use of generic medicines has doubled since 2005 and now accounts for over 75% of total prescriptions issued in the UK. Regulators and policymakers in the UK are highly focused on reducing overall healthcare costs, helping to drive demand for quality generic pharmaceuticals.
Milpharm supplies and distributes generic pharmaceutical products in the UK, offering significant cost advantages to the payer as compared to branded alternatives. Milpharm has grown to now supply over 60 million packs.
Milpharm derives it strength and expertise from its parent company, Aurobindo Pharma which has a presence in over 150 countries worldwide. The group is one of the world’s 10 largest generics companies, measured by revenues. Milpharm is able to supply cost effective pharmaceutical products to its customers from the group’s manufacturing facilities approved by the UK Medicines and Healthcare products Regulatory Agency (MHRA).
Milpharm’ s success is underpinned by its maintenance of a diverse and attractive product portfolio and its strong professionally established relationships with key customers in Wholesale and NHS/ Hospital. The company strives to pro-actively assess changing market conditions to anticipate and meet its customers’ needs.
In the coming years Milpharm has its vision firmly set on further portfolio development in order to increase its support for new and existing customers through the supply of new product lines and established products.
Date of Preparation : July 2025
Reference No: Mil-GB-B-00001(v-0.01)